Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Corneal Ulcer Clinical Trial

Official title:

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05313828
• Other study ID #: soh-med-22-02-28
• Status: Recruiting
• Start date: March 18, 2022
• Est. completion date: July 20, 2022

Study information

• Verified date: April 2022
• Source: Sohag University
• Contact: Hany Mahmoud
• Phone: 00201024368111
• Email: drhanymahmoud[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK. In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: July 20, 2022
• Est. primary completion date: June 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

patients with epithelial viral ulcers -

Exclusion Criteria:

• patients with stromal keratitis patients with corneal opacity

Related Conditions & MeSH terms

• Corneal Ulcer
• Ulcer

Intervention

Drug:
• Acyclovir
acyclovir 4 times /day
• Tobramycin
tobramycin 4 times /day
• Fluorometholone
Fluorometholone 4 times/ day
• Sodium Hyaluronate
Sodium Hyaluronate 4 times/day

Locations

Country	Name	City	State
Egypt	Sohag University	Sohag

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	healing of the epithelium	the epithelial healing assessed with flourescin stain and measured by slit lamp scale in millimetres and compared with pre treatment epithelial defect	10 days follow up